To externally validate the fixed lymphoma cut-off for the IL-6/PCT ratio in a prespecified expansion cohort of B-cell acute lymphoblastic leukaemia (B-ALL) and multiple myeloma (MM). Here, IL6 is linked to precursor B-cell acute lymphoblastic leukemia.